SHA: 603222

Company Drug

Jemincare JMX-2005 PAD Injection Secures NMPA Clinical Trial Approval

Fineline Cube Dec 23, 2025

Jiangxi Jemincare Group (SHA: 603222) announced that its Class 2.2 and Class 2.4 new drug application for...

Company Drug

Jiangxi Jemincare Group Secures Clinical Trial Approvals for Six Drugs in China and the US

Fineline Cube Dec 26, 2023

China-based Jiangxi Jemincare Group (SHA: 603222) has announced receiving clinical trial approvals for six of...

Company Deals

Shyndec Pharmaceutical Licenses Eisai Myonal Generic from ScienPharm – RMB 10.5 Million Deal Targets Muscle Relaxant Market

Company Deals

MSD Reportedly Eyes $6 Billion Terns Pharma Acquisition – BCR-ABL Inhibitor TERN-701 Targets Post-Keytruda Oncology Pipelinew333333

Company Drug

Zhifei Bio Initiates Phase I Study for DTaP-Hib Quadrivalent Vaccine – Component Combination Targets Pediatric Immunization Compliance

Company Drug

Changchun High-Tech Wins FDA Orphan Drug Designation for GenSci128 – TP53 Y220C Reactivator Targets Gastric Cancer